ABOT price forecast

QW Market Intelligence Briefing: Abbott Laboratories (Pakistan) Limited (ABOT)

Disclaimer: This research report is prepared by QW Market Intelligence AI for educational and analytical purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy or sell securities on the Pakistan Stock Exchange (PSX).

---

1. Trend and Momentum Analysis

The quantitative model issues a cautious Sell signal for ABOT at the current price of PKR 925.16, backed by a confidence score of 77 out of 100.

• Trend Structure: The stock is trading below its key 200-day Simple Moving Average (PKR 985.71), indicating a broader medium-to-long-term downward pressure. However, it is hovering close to its 20-day (PKR 928.77) and 50-day (PKR 926.97) SMAs, suggesting a short-term consolidation phase.
• Momentum: The Relative Strength Index (RSI-14) stands at 46.46, reflecting neutral market momentum with a slight negative bias. The Moving Average Convergence Divergence (MACD) shows a minor positive histogram (0.399) despite the MACD line sitting below the signal line, indicating subdued, range-bound price action rather than aggressive selling pressure.

2. The Bull Case (Opportunities)

• Short-Term Support and Consolidation: With the 1-month target projected mildly lower at PKR 901.81 (-2.52%), the downside is currently modeled as relatively shallow rather than a sharp correction.
• Defensive Sector Appeal: As a multinational pharmaceutical firm, Abbott enjoys steady domestic demand for essential medicines, making it a defensive holding during broader macroeconomic volatility on the PSX.
• Potential for Rebound: If macroeconomic indicators improve—such as stabilization in currency or regulatory relief regarding pharmaceutical pricing—the stock could easily test its upper volatility bands.

3. The Bear Case (Risks)

• Downward Targets: Quantitative horizons point to a gradual decline, with a 1-week target of PKR 914.96 (-1.1%) and a 1-month target of PKR 901.81. Lower band projections stretch down to PKR 836.99 over a 1-month horizon.
• Long-Term Resistance: Trading firmly below the 200-day SMA (PKR 985.71) shows that sellers remain in control of the macro trend.
• Margin Pressures: Persistent inflation, high energy costs, and import restrictions on raw pharmaceutical inputs can compress profit margins, a common risk across the Pakistan pharmaceutical sector.

4. Key Levels to Watch

• Resistance / Highs:
• Immediate 1-day high projection: PKR 935.55
• 1-week high projection: PKR 945.86
• 1-month high projection: PKR 966.63
• Major Trend Resistance: 200-day SMA at PKR 985.71
• Support / Lows:
• Immediate 1-day low projection: PKR 907.91
• 1-week low projection: PKR 884.06
• 1-month low/extreme downside boundary: PKR 836.99

5. What Would Invalidate the Forecast?

• Trend Invalidation (Bullish Reversal): A decisive daily and weekly close above the 200-day SMA (PKR 985.71) accompanied by rising volume would break the current downtrend and invalidate the conservative Sell outlook.
• Momentum Shift: A sharp expansion in the MACD histogram alongside an RSI push above the 55–60 threshold would signal building buyer strength, pushing the stock toward its 1-month high projection of PKR 966.63 ahead of schedule.